TELO Telomir Pharmaceuticals, Inc.
TELO financial statements, revenue, balance sheet, cash flow, and SEC filings
Showing 3 of 4 annual and 0 of 14 quarterly periods.
Full history available with a free account or via API.
▼ Company Profile
Filer Category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Entity Type
Operating
Public Float
$18.10M (Jun 2025)
Industry (SIC)
2834 Pharmaceutical Preparations
Incorporated
FL
Fiscal Year End
December (1231)
Phone
786-396-6723
EIN
872606031
Headquarters
MIAMI, FL, 33131
Public Float History
Market value of shares held by public investors, reported in annual DEI filings.
▼ Key Metrics (TTM)
As of Sep 30, 2026Financials
Revenue
-
Net Income
$-5.48M
Total Assets
$4.64M
Total Equity
$4.40M
Total Debt
-
Free Cash Flow
-
Ratios
Return on Equity
-124.4%
Return on Assets
-118%
Current Ratio
19.6x
Sources and calculation details
Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.
Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.
Annual (FY)
Quarterly 🔒
Chart 🔒
| Metric | FY2025 📄 | FY2024 📄 | FY2023 📄 |
|---|---|---|---|
| Income Statement | |||
| REVENUE | |||
| OPERATING EXPENSES | |||
| R&D Expense | $2.44M | $2.24M | $1.57M |
| SG&A Expense | $8.10M | $9.64M | $600.19K |
| NON-OPERATING INCOME / EXPENSE | |||
| Interest Expense | - | - | $1.64M |
| Interest Income | $125.64K | $48.00K | - |
| Net Income | $-10.41M | $-16.53M | $-13.07M |
| PER SHARE & SUPPLEMENTAL | |||
| Diluted EPS | $-0.33 | $-0.56 | $0.48 |
| Diluted Shares | 31.65M | 29.54M | 27.30M |
| Balance Sheet | |||
| ASSETS | |||
| Other Current Assets | $54.69K | $57.87K | $713 |
| Current Assets | $7.34M | $1.32M | $435.23K |
| Noncurrent Assets | $0 | $0 | $4.34M |
| Total Assets | $7.34M | $1.32M | $4.77M |
| LIABILITIES | |||
| Accounts Payable | $536.77K | $587.54K | $707.19K |
| Other Current Liabilities | $318.23K | $93.43K | $527.38K |
| Current Liabilities | $1.43M | $680.97K | $1.34M |
| Other Noncurrent Liabilities | - | - | $527.38K |
| Noncurrent Liabilities | $0 | $0 | $0 |
| Total Liabilities | $1.43M | $680.97K | $1.34M |
| EQUITY | |||
| Additional Paid-in Capital | $46.92M | $31.24M | $17.50M |
| Retained Earnings | $-41.01M | $-30.60M | $-14.06M |
| Total Equity | $5.91M | $643.04K | $3.44M |
| Total Liabilities & Equity | $7.34M | $1.32M | $4.77M |
| SUPPLEMENTAL | |||
| Shares Outstanding | 34.38M | 29.76M | 28.61M |
| Check: A − (L + E + Temp. Equity) | - | - | - |
| Cash Flow Statement | |||
| Cash from Operations | $-3.69M | $-5.07M | $-3.86M |
| Capital Expenditures | - | - | - |
| Cash from Investing | $0 | $0 | $0 |
| Cash from Financing | $9.71M | $6.34M | $3.86M |
| Free Cash Flow | - | - | - |
| Beginning Cash (CFS) | $1.27M | $1.23K | $1.42K |
| Net Change in Cash | $6.02M | $1.26M | $-188 |
| Effect of FX on Cash | - | - | - |
| Calculated Ending Cash | $7.29M | $1.27M | $1.23K |
| Cash per BS | - | - | - |
| Cash scope difference (CFS − BS) | - | - | - |
| Cash per CFS | $7.29M | $1.27M | $1.23K |
Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.
Create Free Account Log In🔒
Quarterly data and charts require a free account
Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.
▼ Frequently Asked Questions
Is Telomir Pharmaceuticals, Inc. profitable?
No. Telomir Pharmaceuticals, Inc. reported $-5.48M in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.
Fundamentals Hub